ERBB2 and breast cancer: Data pertaining to SES, family history of breast cancer, lifestyle factors, human epidermal growth factor receptor 2 status, medical insurance, and the administration of neoadjuvant or adjuvant systemic therapy were limited, preventing us from evaluating these factors as potential confounders or effect modifiers of the relationships observed.